Glymphatic System Dysfunction in Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody–Associated Disorders: Association with Clinical Disability

References

1. 1.↵
   1. Reindl M,
   2. Schanda K,
   3. Woodhall M, et al

   . International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020;7:e674 doi:10.1212/NXI.0000000000000674 pmid:32024795

   Abstract/FREE Full Text
2. 2.↵
   1. Banwell B,
   2. Bennett JL,
   3. Marignier R, et al

   . Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023;22:268–82 doi:10.1016/S1474-4422(22)00431-8 pmid:36706773

   CrossRefPubMed
3. 3.↵
   1. Kim H,
   2. Lee EJ,
   3. Kim S, et al

   . Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm 2020;7:e708 doi:10.1212/NXI.0000000000000708

   Abstract/FREE Full Text
4. 4.↵
   1. Höftberger R,
   2. Guo Y,
   3. Flanagan EP, et al

   . The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 2020;139:875–92 doi:10.1007/s00401-020-02132-y pmid:32048003

   CrossRefPubMed
5. 5.↵
   1. Tanaka S,
   2. Hashimoto B,
   3. Izaki S, et al

   . Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: blood–brain barrier breakdown and peripheral plasmablasts. Mult Scler Relat Disord 2020;41:102005 doi:10.1016/j.msard.2020.102005 pmid:32114369

   CrossRefPubMed
6. 6.↵
   1. Jarius S,
   2. Pellkofer H,
   3. Siebert N, et al

   ; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies, Part 1: results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 2020;17:261 doi:10.1186/s12974-020-01824-2 pmid:32883348

   CrossRefPubMed
7. 7.↵
   1. Takai Y,
   2. Misu T,
   3. Kaneko K, et al

   ; Japan MOG-antibody Disease Consortium. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 2020;143:1431–46 doi:10.1093/brain/awaa102 pmid:32412053

   CrossRefPubMed
8. 8.↵
   1. Kaneko K,
   2. Sato DK,
   3. Nakashima I, et al

   . CSF cytokine profile in MOG-IgG neurological disease is similar to AQP4-IgG NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 2018;89:927–36 doi:10.1136/jnnp-2018-317969 pmid:29875186

   Abstract/FREE Full Text
9. 9.↵
   1. Jarius S,
   2. Metz I,
   3. König FB, et al

   . Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler 2016;22:1541–49 doi:10.1177/1352458515622986 pmid:26869529

   CrossRefPubMed
10. 10.↵
    1. Zarruk JG,
    2. Berard JL,
    3. Passos dos Santos R, et al

    . Expression of iron homeostasis proteins in the spinal cord in experimental autoimmune encephalomyelitis and their implications for iron accumulation. Neurobiol Dis 2015;81:93–107 doi:10.1016/j.nbd.2015.02.001 pmid:25724358

    CrossRefPubMed
11. 11.↵
    1. Ruuls SR,
    2. Bauer J,
    3. Sontrop K, et al

    . Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 1995;56:207–17 doi:10.1016/0165-5728(94)00154-g pmid:7860716

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Iliff JJ,
    2. Wang M,
    3. Liao Y, et al

    . A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012;4:147ra111 doi:10.1126/scitranslmed.3003748 pmid:22896675

    Abstract/FREE Full Text
13. 13.↵
    1. Lohela TJ,
    2. Lilius TO,
    3. Nedergaard M

    . The glymphatic system: implications for drugs for central nervous system diseases. Nat Rev Drug Discov 2022;21:763–79 doi:10.1038/s41573-022-00500-9 pmid:35948785

    CrossRefPubMed
14. 14.↵
    1. Nedergaard M,
    2. Goldman SA

    . Glymphatic failure as a final common pathway to dementia. Science 2020;370:50–56 doi:10.1126/science.abb8739 pmid:33004510

    Abstract/FREE Full Text
15. 15.↵
    1. Liang S,
    2. Lu Y,
    3. Li Z, et al

    . Iron aggravates the depressive phenotype of stressed mice by compromising the glymphatic system. Neurosci Bull 2020;36:1542–46 doi:10.1007/s12264-020-00539-x pmid:32578069

    CrossRefPubMed
16. 16.↵
    1. Gu S,
    2. Li Y,
    3. Jiang Y, et al

    . Glymphatic dysfunction induced oxidative stress and neuro-inflammation in major depression disorders. Antioxidants (Basel) 2022;11:2296 doi:10.3390/antiox11112296 pmid:36421482

    CrossRefPubMed
17. 17.↵
    1. Mogensen FL,
    2. Delle C,
    3. Nedergaard M

    . The glymphatic system (en)during inflammation. Int J Mol Sci 2021;22:7491 doi:10.3390/ijms22147491 pmid:34299111

    CrossRefPubMed
18. 18.↵
    1. Filiano AJ,
    2. Gadani SP,
    3. Kipnis J

    . How and why do T cells and their derived cytokines affect the injured and healthy brain? Nat Rev Neurosci 2017;18:375–84 doi:10.1038/nrn.2017.39 pmid:28446786

    CrossRefPubMed
19. 19.↵
    1. Naganawa S,
    2. Taoka T

    . The glymphatic system: a review of the challenges in visualizing its structure and function with MR imaging. Magn Reson Med Sci 2022;21:182–94 doi:10.2463/mrms.rev.2020-0122 pmid:33250472

    CrossRefPubMed
20. 20.↵
    1. Taoka T,
    2. Masutani Y,
    3. Kawai H, et al

    . Evaluation of glymphatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer's disease cases. Jpn J Radiol 2017;35:172–78 doi:10.1007/s11604-017-0617-z pmid:28197821

    CrossRefPubMed
21. 21.↵
    1. Taoka T,
    2. Ito R,
    3. Nakamichi R, et al

    . Diffusion-weighted image analysis along the perivascular space (DWI-ALPS) for evaluating interstitial fluid status: age dependence in normal subjects. Jpn J Radiol 2022;40:894–902 doi:10.1007/s11604-022-01275-0 pmid:35474438

    CrossRefPubMed
22. 22.↵
    1. Zhang W,
    2. Zhou Y,
    3. Wang J, et al

    . Glymphatic clearance function in patients with cerebral small vessel disease. NeuroImage 2021;238:118257 doi:10.1016/j.neuroimage.2021.118257 pmid:34118396

    CrossRefPubMed
23. 23.↵
    1. Kamagata K,
    2. Andica C,
    3. Takabayashi K, et al

    ; for the Alzheimer’s Disease Neuroimaging Initiative. Association of MRI indices of glymphatic system with amyloid deposition and cognition in mild cognitive impairment and Alzheimer disease. Neurology 2022;99:e2648–60 doi:10.1212/WNL.0000000000201300 pmid:36123122

    CrossRefPubMed
24. 24.↵
    1. Chen HL,
    2. Chen PC,
    3. Lu CH, et al

    . Associations among cognitive functions, plasma DNA, and diffusion tensor image along the perivascular space (DTI-ALPS) in patients with Parkinson’s disease. Oxidative Medicine and Cellular Longevity 2021;2021:1–10.
25. 25.↵
    1. Carotenuto A,
    2. Cacciaguerra L,
    3. Pagani E, et al

    . Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability. Brain 2022;145:2785–95 doi:10.1093/brain/awab454 pmid:34919648

    CrossRefPubMed
26. 26.↵
    1. Cacciaguerra L,
    2. Carotenuto A,
    3. Pagani E, et al

    . Magnetic resonance imaging evaluation of perivascular space abnormalities in neuromyelitis optica. Ann Neurol 2022;92:173–83 doi:10.1002/ana.26419 pmid:35596582

    CrossRefPubMed
27. 27.↵
    1. Marignier R,
    2. Hacohen Y,
    3. Cobo-Calvo A, et al

    . Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021;20:762–72 doi:10.1016/S1474-4422(21)00218-0 pmid:34418402

    CrossRefPubMed
28. 28.↵
    1. Kurtzke JF

    . A new scale for evaluating disability in multiple sclerosis. Neurology 1955;5:580–83 doi:10.1212/wnl.5.8.580 pmid:13244774

    FREE Full Text
29. 29.↵
    1. Fazekas F,
    2. Chawluk JB,
    3. Alavi A, et al

    . MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987;149:351–56 doi:10.2214/ajr.149.2.351 pmid:3496763

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Mohammadi S,
    2. Möller HE,
    3. Kugel H, et al

    . Correcting eddy current and motion effects by affine whole-brain registrations: evaluation of three-dimensional distortions and comparison with slicewise correction. Magn Reson Med 2010;64:1047–56 doi:10.1002/mrm.22501 pmid:20574966

    CrossRefPubMed
31. 31.↵
    1. Becker SM,
    2. Tabelow K,
    3. Voss HU, et al

    . Position-orientation adaptive smoothing of diffusion weighted magnetic resonance data (POAS). Med Image Anal 2012;16:1142–55 doi:10.1016/j.media.2012.05.007 pmid:22677817

    CrossRefPubMed
32. 32.↵
    1. Hagiwara A,
    2. Warntjes M,
    3. Hori M, et al

    . SyMRI of the brain: rapid quantification of relaxation rates and proton density, with synthetic MRI, automatic brain segmentation, and myelin measurement. Invest Radiol 2017;52:647–57 doi:10.1097/RLI.0000000000000365 pmid:28257339

    CrossRefPubMed
33. 33.↵
    1. Egger C,
    2. Opfer R,
    3. Wang C, et al

    . MRI FLAIR lesion segmentation in multiple sclerosis: does automated segmentation hold up with manual annotation? Neuroimage Clin 2017;13:264–70 doi:10.1016/j.nicl.2016.11.020 pmid:28018853

    CrossRefPubMed
34. 34.↵
    1. Schmidt P,
    2. Gaser C,
    3. Arsic M, et al

    . An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage 2012;59:3774–83 doi:10.1016/j.neuroimage.2011.11.032 pmid:22119648

    CrossRefPubMed
35. 35.↵
    1. Fischl B

    . FreeSurfer. Neuroimage 2012;62:774–81 doi:10.1016/j.neuroimage.2012.01.021 pmid:22248573

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Patenaude B,
    2. Smith SM,
    3. Kennedy DN, et al

    . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907–22 doi:10.1016/j.neuroimage.2011.02.046 pmid:21352927

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Taoka T,
    2. Ito R,
    3. Nakamichi R, et al

    . Reproducibility of diffusion tensor image analysis along the perivascular space (DTI-ALPS) for evaluating interstitial fluid diffusivity and glymphatic function: CHanges in Alps index on Multiple conditiON acquIsition eXperiment (CHAMONIX) study. Jpn J Radiol 2022;40:147–58 doi:10.1007/s11604-021-01187-5 pmid:34390452

    CrossRefPubMed
38. 38.↵
    1. Kress BT,
    2. Iliff JJ,
    3. Xia M, et al

    . Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 2014;76:845–61 doi:10.1002/ana.24271 pmid:25204284

    CrossRefPubMed
39. 39.↵
    1. Ren Z,
    2. Iliff JJ,
    3. Yang L, et al

    . ‘Hit & Run’ model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulation. J Cereb Blood Flow Metab 2013;33:834–45 doi:10.1038/jcbfm.2013.30 pmid:23443171

    CrossRefPubMed
40. 40.↵
    1. Wang M,
    2. Iliff JJ,
    3. Liao Y, et al

    . Cognitive deficits and delayed neuronal loss in a mouse model of multiple microinfarcts. J Neurosci 2012;32:17948–60 doi:10.1523/JNEUROSCI.1860-12.2012 pmid:23238711

    Abstract/FREE Full Text
41. 41.↵
    1. Rustenhoven J,
    2. Drieu A,
    3. Mamuladze T, et al

    . Functional characterization of the dural sinuses as a neuroimmune interface. Cell 2021;184:1000–16.e27 doi:10.1016/j.cell.2020.12.040 pmid:33508229

    CrossRefPubMed
42. 42.↵
    1. Ivan DC,
    2. Walthert S,
    3. Berve K, et al

    . Dwellers and trespassers: mononuclear phagocytes at the borders of the central nervous system. Front Immunol 2020;11:609921 doi:10.3389/fimmu.2020.609921 pmid:33746939

    CrossRefPubMed
43. 43.↵
    1. Zhou H,
    2. Andonegui G,
    3. Wong CHY, et al

    . Role of endothelial TLR4 for neutrophil recruitment into central nervous system microvessels in systemic inflammation. J Immunol 2009;183:5244–50 doi:10.4049/jimmunol.0901309 pmid:19786543

    Abstract/FREE Full Text
44. 44.↵
    1. Salvador AF,
    2. de Lima KA,
    3. Kipnis J

    . Neuromodulation by the immune system: a focus on cytokines. Nat Rev Immunol 2021;21:526–41 doi:10.1038/s41577-021-00508-z pmid:33649606

    CrossRefPubMed
45. 45.↵
    1. Duan Y,
    2. Zhuo Z,
    3. Li H, et al

    . Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. J Neurol Neurosurg Psychiatry 2021;92:709–16 doi:10.1136/jnnp-2020-324826 pmid:33687975

    Abstract/FREE Full Text
46. 46.↵
    1. Naganawa S,
    2. Taoka T,
    3. Ito R, et al

    . The glymphatic system in humans: investigations with magnetic resonance imaging. Invest Radiol 2023 Mar 13 [Epub ahead of print] doi:10.1097/RLI.0000000000000969

    CrossRef
47. 47.↵
    1. Pla V,
    2. Bork P,
    3. Harnpramukkul A, et al

    . A real-time in vivo clearance assay for quantification of glymphatic efflux. Cell Rep 2022;40:111320 doi:10.1016/j.celrep.2022.111320 pmid:36103828

    CrossRefPubMed